Vertex Pharmaceuticals' non-opioid pain medication gets FDA approval
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more than 20 years.
US open: Stocks jump on the back of slightly better-than-expected data
Wall Street was moving higher still shortly after the open, on the back of slightly better-than-expected readings for US ...
Vertex Pharmaceuticals price target raised to $545 from $520 at BMO Capital
BMO Capital analyst Evan Seigerman raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $545 from $520 and keeps an Outperform ...